Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.

European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations

Open access
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H.A., Calzavara Pinton, P., Christen‐Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink‐Wagner, A.H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C.G., Nast, A., Nygaard, U., Redding, M., Rehbinder, E.M., Ring, J., Rossi, M., Serra‐Baldrich, E., Simon, D., Szalai, Z.Z., Szepietowski, J.C., Torrelo, A., Werfel, T., Flohr, C.·2022·Journal of the European Academy of Dermatology and Venereology

Abstract

The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty‐nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti‐inflammatory treatment, antimicrobial and antipruritic treatment and UV phototherapy. Furthermore, this part of the guideline covers techniques for avoiding provocation factors, as well as dietary interventions, immunotherapy, complementary medicine and educational interventions for patients with atopic eczema and deals with occupational and psychodermatological aspects of the disease. It also contains guidance on treatment for paediatric and adolescent patients and pregnant or breastfeeding women, as well as considerations for patients who want to have a child. A chapter on the patient perspective is also provided. The first part of the guideline, published separately, contains recommendations and guidance on systemic treatment with conventional immunosuppressive drugs, biologics and janus kinase (JAK) inhibitors, as well as information on the scope and purpose of the guideline, and a section on guideline methodology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.18429

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 181 references

Cited by

See all 289

Metadata

Authors
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink‐Wagner, A. H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., Gregoriou, S., Mortz, C. G., Nast, A., Nygaard, U., Redding, M., Rehbinder, E. M., Ring, J., Rossi, M., Serra‐Baldrich, E., Simon, D., Szalai, Z. Z., Szepietowski, J. C., Torrelo, A., Werfel, T., & Flohr, C.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2022-09-03
Volume
36
Issue
11
Pages
1904-1926
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W4294376130
Cited by
289
References
181
FWCI
47.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations. https://app.cochat.ai/papers/10.1111/jdv.18429
The paper
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., Deleuran, M., Dittmann, M., Dressler, C., Fink‐Wagner, A. H., Fosse, N., Gáspár, K., Gerbens, L., Gieler, U., Girolomoni, G., . . . Flohr, C. (2022). European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18429

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.